Sharing Treatment Strategies and Clinical Data for Benign Prostatic Hyperplasia

JW Pharmaceutical and JW Shinyak announced on the 10th that they held the "J STAR Symposium" at the Grand Walkerhill Seoul for two days starting from the 30th of last month to share the clinical usefulness and safety of "Truepass" (active ingredient: Silodosin).


JW Pharmaceutical and JW Shinyak held the ‘J STAR Symposium’ for two days from the 30th of last month at the Grand Walkerhill Seoul, sharing the clinical usefulness and safety of ‘Trupath (active ingredient Silodosin)’. JW Holdings

JW Pharmaceutical and JW Shinyak held the ‘J STAR Symposium’ for two days from the 30th of last month at the Grand Walkerhill Seoul, sharing the clinical usefulness and safety of ‘Trupath (active ingredient Silodosin)’. JW Holdings

View original image

Truepass is an alpha-blocker that improves urinary symptoms associated with benign prostatic hyperplasia by relaxing the muscles surrounding the prostate. It selectively blocks the "α1A receptor," which is concentrated in the prostate and bladder neck, thereby relieving urethral tension and effectively improving symptoms of urinary dysfunction.


This symposium, targeting urology specialists, was organized to share safe prescription strategies for patients with benign prostatic hyperplasia and present key clinical data of Truepass.


On the first day of the symposium, the 30th of last month, Professor Yoo Sangjun from Seoul National University Boramae Medical Center’s Department of Urology delivered a presentation on "Rapid Symptom Improvement and Achieving Efficacy in the Treatment of Benign Prostatic Hyperplasia." Professor Yoo explained the importance of early symptom relief and continuous management of urinary function in treating benign prostatic hyperplasia.


Professor Yoo stated, "There are distinct differences in the clinical efficacy and safety among alpha-blockers in treating benign prostatic hyperplasia. Truepass not only provides rapid and potent improvement for bladder outlet obstruction (BOO), but also effectively alleviates nocturia and overactive bladder (OAB) symptoms, while offering cardiovascular safety."


In the subsequent session, Professor Bae Sangrak from the Department of Urology at The Catholic University of Korea Uijeongbu St. Mary’s Hospital gave a lecture on "Improvement of Nocturia and Sleep Disorders by Silodosin." Professor Bae emphasized, "Among lower urinary tract symptoms (LUTS), nocturia repeatedly reduces patients’ quality of sleep and directly impacts their quality of life. In European Phase 3 approval trials, silodosin was shown to improve urinary symptoms in patients with benign prostatic hyperplasia and reduce the frequency of nocturia, with additional clinical data reporting improvements in residual urine-related indicators." He added, "Preclinical studies have confirmed the potential of silodosin to improve bladder blood flow, making it a suitable treatment option for patients who urgently need relief from nocturnal urinary symptoms."


On the 31st, Professor Park Sangmin from the Department of Cardiology at Nowon Eulji Medical Center delivered a presentation titled "Cardiovascular Considerations in Alpha-Blocker Therapy," discussing the use of alpha-blockers for patients with benign prostatic hyperplasia accompanied by hypertension. He addressed treatment strategies considering blood pressure changes, heart failure, cognitive decline, and the risk of orthostatic hypotension.


Professor Park explained, "From a cardiology perspective, dizziness, fainting, and fall risks due to orthostatic hypotension must be carefully considered when prescribing alpha-blockers to patients with benign prostatic hyperplasia. If alpha-blockers also block the α1B receptors of vascular smooth muscle, this can cause peripheral vasodilation and systemic blood pressure reduction, potentially leading to such side effects. Therefore, extra caution is needed when prescribing for elderly patients with chronic diseases." He added, "The risks are especially higher for patients with hypertension, diabetes, cardiovascular disease, or those taking multiple medications. Thanks to its high α1A selectivity, Truepass minimizes the impact on blood pressure, making it a relatively safe prescription option."


JW Pharmaceutical and JW Shinyak plan to enhance product reliability in the field of benign prostatic hyperplasia treatment by focusing on the main clinical evidence for Truepass and its practical applications in real-world medical settings.



A representative from JW Pharmaceutical stated, "When treating benign prostatic hyperplasia, it is important to consider not only the improvement of urinary symptoms but also patients’ comorbidities and concomitant medications. Based on the selective α1A receptor blocking mechanism and clinical data of Truepass, we will strive to contribute to the treatment of patients with benign prostatic hyperplasia."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing